Systemic and ocular complications related to intravitreal administration of anti-VEGF agents. [PDF]
Med Hypothesis Discov Innov OphthalmolKoksaldi S +3 more
europepmc +1 more source
Efficacy of a single dose switch from aflibercept to ranibizumab in the treatment of neovascular age-related macular degeneration. [PDF]
PLoS OneIby J +6 more
europepmc +1 more source
Faricimab for choroidal neovascular membrane secondary to choroidal osteoma: A case report. [PDF]
J Int Med ResAl Adel F +3 more
europepmc +1 more source
Expanding horizons of intravitreal anti-vascular endothelial growth factor therapy in retinal diseases. [PDF]
Indian J OphthalmolSingh S, Kala U, Bamel A, Agarwal M.
europepmc +1 more source
Intravitreal Anti-VEGF Injection Transitions Across Bevacizumab, Biosimilar, and Branded Medications: The IRIS Registry Study. [PDF]
J Vitreoretin DisBerkowitz ST +8 more
europepmc +1 more source
A comparative study on the efficacy and safety of biosimilar (Rimmyrah) and reference ranibizumab in patients with diabetic macular edema. [PDF]
Front PharmacolZhai G, Ren X, Xu B, Mi D.
europepmc +1 more source
Visual Outcomes Following Infectious Endophthalmitis from Intravitreal Injections of Biologic Drugs: An Intelligent Research in Sight Registry Retrospective Analysis. [PDF]
Ophthalmol TherZhang R, Tunon-Robinson I, Nguyen AK.
europepmc +1 more source
Reassessing high-dose ranibizumab in the era of durable anti-VEGF therapy. [PDF]
Front Ophthalmol (Lausanne)Cheng CK, Tsai CJ, Bai CH.
europepmc +1 more source
Case Report: Perifoveal exudative vascular anomalous complex with secondary fundus hemorrhage. [PDF]
Front Med (Lausanne)Liu Z +7 more
europepmc +1 more source
Cost-effectiveness analysis of the use of faricimab in diabetic macular edema in China. [PDF]
J Comp Eff ResShi F +6 more
europepmc +1 more source